Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era

フォーマット:

論文

責任表示:

Takamatsu, Hiroyuki ; Honda, Sumihisa ; Miyamoto, Toshihiro ; Yokoyama, Kenji ; Hagiwara, Shotaro ; Ito, Toshiro ; Tomita, Naoto ; Iida, Shinsuke ; Iwasaaki, Toshihiro ; Sakamaki, Hisashi ; Suzuki, Ritsuro ; Sunami, Kazutaka

言語:

英語

出版情報:

Japanese Cancer Association / Blackwell Publishing Ltd, 2015-02-01

著者名:

Takamatsu, Hiroyuki

Honda, Sumihisa

Miyamoto, Toshihiro

Yokoyama, Kenji

Hagiwara, Shotaro

Ito, Toshiro

Tomita, Naoto

Iida, Shinsuke

Iwasaaki, Toshihiro

Sakamaki, Hisashi

Suzuki, Ritsuro

Sunami, Kazutaka

続きを見る

掲載情報:

Cancer Science

ISSN:

1347-9032      

巻:

106

通号:

2

開始ページ:

179

終了ページ:

185

バージョン:

publisher

概要:

We evaluated the clinical significance of prognostic factors including the International Staging System (ISS) and modified European Group for Blood and Marrow Transplantation response criteria in 1650 Japanese patients with multiple myeloma (MM) who underwent upfront single autologous stem cell transplantation (ASCT). We categorized patients into two treatment cohorts: pre-novel agent era (1995-2006) and novel agent era (2008-2011). The combined percentage of pre-ASCT … complete response and very good partial response cases (463 of 988, 47%) significantly increased during the novel agent era compared with the pre-novel agent era (164 of 527, 31%; P < 0.0001). The 2-year overall survival (OS) rate of 87% during the novel agent era was a significant improvement relative to that of 82% during the pre-novel agent era (P = 0.019). Although significant differences in OS were found among ISS stages during the pre-novel agent era, no significant difference was observed between ISS I and II (P = 0.107) during the novel agent era. The factors independently associated with a superior OS were female gender (P = 0.002), a good performance status (P = 0.024), lower ISS (P < 0.001), pre-ASCT response at least partial response (P < 0.001) and ASCT during the novel agent era (P = 0.017). These results indicate that the response rate and OS were significantly improved, and the ISS could not clearly stratify the prognoses of Japanese patients with MM who underwent upfront single ASCT during the novel agent era. © 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association. 続きを見る

URL:

http://hdl.handle.net/2297/45512